For research use only. Not for human or veterinary use. 21+.
Buy one, get one freeOn every vial · no code neededShop the offer
MANUFACTURED & SHIPPED FROM THE USA
CJC-1295 + Ipamorelin 5 / 5 mg — Peptides Only, research use only
Blends · GH Axis

CJC-1295 + Ipamorelin

99.96% purity · Lot 78WS7U · tested May 12, 2026

The classic GH-axis pairing, pre-combined 1:1.

  • Independently tested
  • Lot-matched COA
  • Lyophilized for stability
  • Ships from the USA
Research use only. Not for human or veterinary use. Sold to qualified researchers aged 21+.
$145.002 for $145 — $72.50 per vial
Buy one, get one free. Mix and match any 2 eligible vials and the lower-priced one is free — applied automatically. One-time purchases only.
1
CJC-1295 + Ipamorelin$145.002 for $145
Lot-matched documentation. Every order ships with the certificate for its lot. If a vial arrives damaged or doesn't match its paperwork, tell us within 72 hours and we'll replace it.

Latest lab results

Third-party tested

CJC-1295 + Ipamorelin 5 / 5 mg

Purity (HPLC-UV)
99.96%
Identity (LC-MS)
Confirmed — CJC-1295 / Ipamorelin
Net content
Ipamorelin 7.97 mg (label 5 / 5 mg)
Lot
78WS7U
Tested
May 12, 2026
Lab
Freedom Diagnostics Testing
View certificate (PDF)

Your order ships with the certificate for its own lot. 1 earlier certificate for this size in the COA library.

About CJC-1295 + Ipamorelin

The classic GH-axis pairing, pre-combined 1:1.

Supplied as

5 / 5 mg per vial, as a lyophilized powder in a sealed glass vial with a crimped cap. The lot number on the label matches the certificate of analysis in the COA library.

Storage and handling

Store lyophilized powder frozen (−20 °C) or refrigerated, sealed and away from light. Once reconstituted, keep refrigerated (2–8 °C).

Handle in a laboratory setting using appropriate protective equipment. Consult the certificate of analysis and safety data for lot-specific information.

Important research notice. This product is intended solely for in-vitro and laboratory research. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be used in humans or animals. Peptides Only does not provide usage or dosing information.

Research summary

CJC-1295 + Ipamorelin is a single lyophilized vial containing 5 mg of CJC-1295 without DAC (modified GRF 1-29, a GHRH analogue) and 5 mg of ipamorelin (a ghrelin-receptor agonist). The two peptides act on different receptors on the same pituitary cells, and studies combining GHRH with GH-releasing peptides have reported synergistic growth hormone (GH) release1. No published study has tested this exact combination.

Also known as
CJC-1295/Ipamorelin · Mod GRF (1-29) + Ipamorelin · CJC-1295 no DAC + Ipamorelin

What's in the vial

  • CJC-1295 without DAC, 5 mg: the tetrasubstituted GHRH(1-29) amide that forms the backbone of CJC-12952, without the albumin-binding lysine. A preparation sold under the CJC-1295 name and analyzed by a doping-control laboratory proved to be this 29-residue peptide3.
  • Ipamorelin, 5 mg: a pentapeptide agonist of the growth hormone secretagogue receptor that, in swine, released GH without raising ACTH or cortisol beyond GHRH-stimulated levels4.

Why a GHRH analogue and a ghrelin-receptor agonist are studied together

GHRH acts through its own G protein-coupled receptor, found predominantly in the anterior pituitary and signaling through cyclic AMP5. GH secretagogues act through a separate receptor, GHS-R, cloned in 19966. In cells engineered to express the human GHRH receptor, the secretagogue GHRP-2 did not act through it7.

Because the receptors differ, their effects can exceed the sum of each alone. In healthy men, submaximal amounts of a GH-releasing hexapeptide given with GHRH released GH synergistically1, and the same was later shown for ghrelin itself with GHRH8. The link runs both ways: blocking endogenous GHRH with an antagonist removed most of the GH response to GHRP-6 in men9. These studies used native GHRH, ghrelin and GHRP-6 or similar peptides, not CJC-1295 or ipamorelin.

What has and has not been studied

Because the vial holds two peptides, its certificate should confirm both identities. Every Peptides Only lot ships with a lot-matched certificate of analysis (HPLC purity and mass-spec identity) from an independent lab, published at our COA library. For the difference between the two CJC-1295 forms, see CJC-1295 with DAC vs without DAC.

  • Ipamorelin alone has human pharmacokinetic data: a terminal half-life of about 2 hours and a single GH peak after intravenous infusion in healthy men10.
  • The human studies published under the CJC-1295 name used the long-acting DAC compound, not the version in this vial11.
  • No published study has tested CJC-1295 without DAC together with ipamorelin, in a 1:1 ratio or any other. The case for the pairing rests on the receptor and synergy research above.

CJC-1295 + Ipamorelin FAQ

Does this blend use CJC-1295 with DAC or without DAC?

Without DAC. The CJC-1295 in this vial is the 29-residue modified GRF (1-29) peptide; the long-acting version is sold separately as CJC-1295 with DAC.

Has the CJC-1295 and ipamorelin combination been studied?

Not as a combination. Each component has its own literature, and GHRH-plus-secretagogue synergy has been shown with other peptides1,8, but no published study tests this pair.

Is the blend different from the two peptides bought separately?

It contains the same two peptides, pre-combined at a fixed 1:1 ratio by mass in one vial. Both are also available on their own as CJC-1295 without DAC and ipamorelin.

Is CJC-1295 + Ipamorelin FDA-approved?

No. Neither component is an approved medicine, and the blend is supplied for laboratory research only.

Further reading

References

  1. Bowers CY, Reynolds GA, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. PubMed 2108187
  2. Jetté L, Léger R, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. PubMed 15817669
  3. Henninge J, Pepaj M, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-50. PubMed 21204297
  4. Raun K, Hansen BS, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822
  5. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-44. PubMed 1333056
  6. Howard AD, Feighner SD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. PubMed 8688086
  7. Chen C, Farnworth P, et al. Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells. Endocrine. 1998;9(1):71-7. PubMed 9798733
  8. Hataya Y, Akamizu T, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):4552. PubMed 11549707
  9. Pandya N, DeMott-Friberg R, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-9. PubMed 9543138
  10. Gobburu JV, Agersø H, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. PubMed 10496658
  11. Teichman SL, Neale A, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683

Research summary reviewed 2026-10-26 against the cited literature.

More Blends

You might also need

View all
GLOW Blend 70 mg — Peptides Only, research use onlyBuy One Get One
Lyophilized vial

GLOW Blend

GHK-Cu, BPC-157 and TB-500 blended for skin-matrix research.

$200.00
2 for $200 · $100/vial

Contact Peptides Only

Operated by DND Wellness LLC · 1309 Coffeen Ave, Suite 1200, Sheridan, WY 82801.

support@peptides-only.com · (508) 404-8124

Use the chat widget to ask a question. Informational and promotional text messages require separate, optional consent. Message frequency varies. Msg & data rates may apply. Reply STOP to unsubscribe or HELP for help. Consent is not a condition of purchase. 21+.

SMS consent & support · SMS terms & Terms of Service · Privacy Policy